JPRN-UMIN000006513招募中1 期
Phase 1/2 study of the combination of Bendamustine and Rituximab for treatment of elderly relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma. - Phase 1/2 study of Bendamustine and Rituximab for elderly relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma.
Kinki University School of Medecine Division of Hematology0 个研究点目标入组 43 人开始时间: 2011年10月18日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 43
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 65years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Patients are pregnant or lactating women. Patients (<1 year after menopause, without surgical infertility) can't or will not use birth control during the treatment. 2. Patients have active other malignant diseases including simultaneous cancer and disease free state within 5 years after treatment for other cancer except curable intramural cancer by local treatment. 3. Patients have mental disease or disorder with difficulty in participating in the clinical trial. 4. HBs antigen positive 5. HCV antibody positive 6. HIV antibody positive 7. Patients have much tumor cell in peripheral blood (>=25,000/uL). 8. Patients received allogeneic hematopoietic [hemopoietic] stem cell transplant. 9. Patients have interstitial lung disease or fibroid lung. 10. Patients have CNS invasion. 11. Patients already received bendamustine treatment. 12. Patients are inappropriate for rituximab treatment. 13. Patients have severe allergic symptoms. 14. Inadequate for clinical trial entry by the attending physicians.
研究者
相似试验
招募中
1 期
Phase 1/2 study of the combination of Bendamustine and Rituximab for treatment of relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma.relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphomaJPRN-UMIN000005428Department of Hematology, International Medical Center, Saitama Medical University40
进行中（未招募）
不适用
Phase II study of the combination Bendamustine and sc Alemtuzumab for patients with refractory or relapsed B-cell chronic lynphocytic leukemia - BEN-CAMEUCTR2008-001824-30-ITAssociazione Malattie Sangue Onlus
进行中（未招募）
不适用
A Phase II study of Bendamustine in Combination With Rituximab as Initial Treatment for Patients With Indolent non-follicular Non-Hodgkin’s LymphomaPatients with advanced untreated Indolent non Follicular non-Hodgkin LymphomasMedDRA version: 14.1Level: PTClassification code 10065856Term: Non-Hodgkin's lymphoma unspecified histology indolentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-019248-37-ITFONDAZIONE ITALIANA LINFOMI ONLUS
招募中
2 期
Clinical trials for HDC / ASCT indication rrDLBCRelapsed or recurrent diffuse large B-cell lymphomaJPRN-jRCTs071210121Terui Yasuhito20
进行中（未招募）
不适用
Multicentre phase II trial of Bendamustine in combination with rituximab for patients with previously untreated or relapsed chronic lymphocytic leukemia - CLL2Mpreviously untreated or relapsed chronic lymphocytic leukemiaEUCTR2005-001596-34-DEniversität zu Köln95